RELMADA THERAPEUTICS, INC.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2013
- $5.1K
- Net income
- -$57.4M
- Total assets
- $94.0M
- Market cap
- $624.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $59.1M
- Operating income
- -$59.1M
- Net income
- -$57.4M
- EPS (basic)
- $-1.45
- EPS (diluted)
- $-1.45
Balance sheet
- Total assets
- $94.0M
- Current assets
- $94.0M
- Total liabilities
- $7.5M
- Current liabilities
- $6.4M
- Shareholders’ equity
- $86.5M
Cash flow
- Operating cash flow
- -$45.8M
- Investing cash flow
- -$48.1M
- Financing cash flow
- $93.6M
- Net cash flow
- -$360.5K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $624.1M
- EPS (diluted)
- $-1.45
- Shares outstanding
- 109.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 3, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $57.4M in FY2013.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RELMADA THERAPEUTICS, INC..
Write a review
News about RELMADA THERAPEUTICS, INC.
News & sentiment via Polygon.io
